• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Balkan Journal of Medical Genetics : BJMG >Differential Expression of FGFRs Signaling Pathway Components in Bladder Cancer: A Step Toward Personalized Medicine
【2h】

Differential Expression of FGFRs Signaling Pathway Components in Bladder Cancer: A Step Toward Personalized Medicine

机译：FGFRs信号通路成分在膀胱癌中的差异表达：迈向个性化医学的一步

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Variations Improper activation and inappropriate expression of fibroblast growth factor receptors (FGFRs) in cancer suggests that they can act as therapeutic targets. Fibroblast growth factor receptor inhibitors are currently employed in clinical trials of different cancers. Regarding the essence and the importance of the personalized medicine, mainly mirrored by remarkable inter-individual variations in different populations, we aimed to perform a pilot study to address FGFR1 and FGFR3 expression levels and their correlation with the clinicopathological features in Iranian patients with bladder cancer (BC). Paired tumor and adjacent non tumor tissue samples along with their clinico-pathological parameters were obtained from 50 cases diagnosed with BC in different stages and grades. The mRNA expressions of FGFR1 and FGFR3 in tissue samples were determined by real-time polymerase chain reaction (real-time PCR). The expression levels of FGFR3 were significantly higher in tumor tissues when compared to adjacent normal tissues (p = 0.007), regardless of the stages and grades of the tumor. Over expression was associated with cigarette smoking (p = 0.037) and family history for cancer (p = 0.004). Decreased expression of FGFR1 was observed, remarkably evident in high-grade tumors (p = 0.047), while over expression was detected in low-grade samples. This pilot study clearly suggests that in Iranian BC patients FGFR1 and FGFR3 expression patterns are different, and also highly distinctive with regard to the tumor’s stage and grade. Such particular expression patterns may indicate their special values to be employed for interventional studies aiming targeted therapy. Further studies with a larger sample size are needed to validate our results.
机译：变异癌症中成纤维细胞生长因子受体（FGFRs）活化不当和表达不当表明它们可以充当治疗靶标。目前，成纤维细胞生长因子受体抑制剂被用于不同癌症的临床试验中。关于个性化药物的本质和重要性，主要是通过不同人群之间个体差异的明显反映，我们旨在进行一项初步研究，以解决伊朗膀胱癌患者中FGFR1和FGFR3表达水平及其与临床病理特征的相关性（公元前）。配对的肿瘤和邻近的非肿瘤组织样本及其临床病理参数是从50例诊断为不同阶段和等级的BC患者中获得的。通过实时聚合酶链反应（实时PCR）测定组织样品中FGFR1和FGFR3的mRNA表达。与相邻的正常组织相比，FGFR3在肿瘤组织中的表达水平明显更高（p = 0.007），而与肿瘤的分期和等级无关。高表达与吸烟有关（p = 0.037）和癌症家族史（p = 0.004）。观察到FGFR1表达降低，在高级别肿瘤中显着表现（p = 0.047），而在低级别样品中发现过表达。这项初步研究清楚地表明，在伊朗的BC患者中，FGFR1和FGFR3的表达方式是不同的，并且在肿瘤的分期和等级方面也非常有特色。这样的特定表达模式可以指示它们的特殊值，以用于针对靶向治疗的介入研究。需要进行更大样本量的进一步研究以验证我们的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号